Showing results 1 to 1 of 1
Title | Author(s) | Issue Date | |
---|---|---|---|
Bone and renal safety Are improved in chronic HBV patients switched to tenofovir alafenamide after either 2 or 3 years of prior tenofovir disoproxil fumarate treatment. Proceeding/Conference:Liver Week, Korean Association for the Study of the Liver | 2019 |